Valerie Hoffman is the Head of Research with Meru Health. She received her MPH from Yale University and doctorate in psychiatric epidemiology from Johns Hopkins University’s Bloomberg School of Public Health. She has over 20 years of experience in designing studies, analyzing findings, and reporting results in over 80 peer-reviewed publications. Dr. Hoffman has been the Principal Investigator of NIH, VA, SAMHSA, AHRQ, DoD, and CDC-funded studies and currently is conducting a randomized controlled trial to test the efficacy of the Meru Health Program.
What is the biggest thing you learned in 2020?
What do you feel are the two most important benefits or areas that need to be a top priority in 2021?
Can you share a story on an area of your healthcare program or employee benefits where you were able to create significant savings or stop costs from rising?
If you could automatically receive a 10-20% reduction in costs in three areas/programs, what would your dream list be?
What is the most innovative program you will focus on in 2021 and/or 2022?
How are you re-imagining corporate culture & well-being?
What virtual care solutions did you roll out during the pandemic? How valuable were they and why?
If you look at our 3 Moonshots - Costs, Culture, and Care; In one sentence, tell us what would be something positive for us to take from 2020 and bring into this new year?